Denali Therapeutics Inc
DNLI
NASDAQ
Biotechnology
$24.40
USD
-0.42 (-1.69%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $4.05B
Volume 876.2K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-508.02M
TTM
-11.9%
YoY
Operating Cash Flow
$-412.34M
TTM
-12.8%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 29.4 | 32.3 | 35.5 | 39.5 | 33.5 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 145.6 | 135.0 | 137.4 | 137.4 | 137.4 |
Operating Income | -145.6 | -135.0 | -137.4 | -137.4 | -137.4 |
EBITDA | -143.3 | -128.9 | -134.5 | -134.5 | -134.5 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 12.6 | 10.8 | 10.5 | 8.9 | 8.9 |
Income Before Income Taxes | -133.0 | -124.1 | -126.9 | -128.4 | -128.4 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 |
Net Income | -133.0 | -124.1 | -126.9 | -128.5 | -128.4 |
Consolidated Net Income / Loss | -133.0 | -124.1 | -126.9 | -128.5 | -128.4 |
Net Income Attributable to Common Shareholders | -133.0 | -124.1 | -126.9 | -128.5 | -129.8 |
Basic EPS | -$0.78 | -$0.72 | -$0.74 | -$0.73 | -$0.69 |
Diluted EPS | -$0.78 | -$0.72 | -$0.74 | -$0.73 | -$0.69 |
Basic Shares Outstanding | 171.2M | 171.4M | 172.4M | 175.5M | 186.6M |
Diluted Shares Outstanding | 171.2M | 171.4M | 172.4M | 175.5M | 186.6M |